Key messages 

• The 10-year results of the Short-HER trial show that disease-free survival (DFS) and overall survival (OS) are very similar after standard (12 months) and short (9 weeks) adjuvant treatment with trastuzumab in patients with early-stage HER2 breast cancer.

• Patients with four or more positive lymph nodes ...